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Abstract
Adaptive designs for multi-armed clinical trials have become in-
creasingly popular recently in many areas of medical research because
of their potential to shorten development times and to increase patient
response. However, developing response-adaptive trial designs that of-
fer patient benefit while ensuring the resulting trial avoids bias and pro-
vides a statistically rigorous comparison of the different treatments in-
cluded is highly challenging. In this paper, the theory of Multi-Armed
Bandit Problems is used to define a family of near optimal adaptive
designs in the context of a clinical trial with a normally distributed
endpoint with known variance. Through simulation studies based on
an ongoing trial as a motivation we report the operating characteristics
(type I error, power, bias) and patient benefit of these approaches and
compare them to traditional and existing alternative designs. These
results are then compared to those recently published in the context
of Bernoulli endpoints. Many limitations and advantages are similar
in both cases but there are also important differences, specially with
respect to type I error control. This paper proposes a simulation-based
testing procedure to correct for the observed type I error inflation that
bandit-based and adaptive rules can induce. Results presented extend
∗Corresponding author. Email: sofia.villar@mrc-bsu.cam.ac.uk
1
ar
X
iv
:1
70
3.
05
17
2v
1 
 [s
tat
.A
P]
  1
5 M
ar 
20
17
recent work by considering a normally distributed endpoint, a very
common case in clinical practice yet mostly ignored in the response-
adaptive theoretical literature, and illustrate the potential advantages
of using these methods in a rare disease context. We also recommend a
suitable modified implementation of the bandit-based adaptive designs
for the case of common diseases.
Keywords: Multi-armed bandit; Gittins index; response adaptive proce-
dures; normally distributed endpoint; sequential sampling; patient allocation.
1 Introduction
The medical and statistical communities have long held as a ‘gold standard’
for clinical trials the so-called randomised controlled trial (RCT), where pa-
tients are allocated to a treatment arm with a fixed probability which is
equal across all arms and for all patients. This scheme ensures the trial is
well-balanced, eliminates possible sources of bias, and makes the results as
sound as possible. However, this design makes no concession to the wellbeing
of patients in the trial: in a K-arm RCT, on average K−1
K
of the patients will
be assigned to a treatment other than the most effective one (if it exists).
This creates one of the foremost ethical concerns inherent in any clini-
cal trial: the conflict between learning (ensuring the selection of the best
treatment) and earning (treating most patients effectively). The scientific
aim of a traditional RCT is to learn about new treatments and identify the
most effective one. It is inevitable under this paradigm, however, that a
fixed number of patients will be given an inferior treatment. The research on
adaptive methods for trial designs, such as response-adaptive randomisation
methods, has developed as a response to this ethical dilemma, seeking to
improve the earning resulting from a trial while preserving its learning. The
challenge is to find response-adaptive methods which improve patient welfare
during the trial, but do not allow extreme imbalance or bias to hinder the
statistical validity of the trial, and are conclusive enough truly to influence
future medical practice.
The need to consider patients’ wellbeing during the trial is particularly
acute in the case of a treatment for a rare disease. In this situation the trial
patients represent a high proportion of all those with the disease, and a trial
aiming solely to identify the most effective treatment will benefit only the
small number of patients remaining to be treated after the end of the trial.
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The ethical concerns with randomising patients onto an inferior treatment
are most severe in the case of a serious or life-threatening disease. Thus, the
motivation for an adaptive trial design is arguably strongest in the case of life-
threatening rare diseases such as the new types of rare cancers identified by
the advances of genetics. However, the challenges of maintaining statistical
rigour are even more acute when recruitable patients are sparse and sample
sizes are small.
The majority of the response-adaptive randomisation methods proposed
in the literature use Bayesian learning and a binary endpoint, with infor-
mation on the effectiveness of the treatments gained throughout the trial
deployed immediately, to increase the chances of patients in the trial re-
ceiving a better performing treatment (see e.g. [22]). A limitation of these
approaches is that they are myopic (they only make use of past information
to alter treatment allocation probabilities) and hence they are not influenced
at all by the number of patients that remain to be treated in the trial (nor
by the expected number of patients outside the trial). An approach recently
proposed and modified for addressing this limitation and developing “forward
looking algorithms” is to consider clinical trial design within the framework
of the Multi-Armed Bandit Problem (MABP). The optimal solution to the
classic MABP has been known since the 1970s [7], and those responsible for
its solution saw clinical trials as the “chief practical motivation” for their
work [8, p. 561]; despite this, it has never been applied to a real life clinical
trial. [23, pp. 2-3]
In [23] some of the benefits and limitations of applying the MABP solu-
tion to clinical trials are explored, considering in particular the case where
the trial’s primary endpoint is dichotomous (i.e. the treatment arms are
modelled as reward processes by Bernoulli random variables). The objective
of the paper is two-fold. The first is to apply some of the considerations and
techniques of [23] to define a response-adaptive Bayesian design for a clinical
trial whose primary endpoint is normally distributed with known variance, a
case that has been less commonly studied in the response-adaptive literature.
Specifically, we investigate whether the same conclusions in terms of patient
benefit and operating characteristics hold as in the case of trials with binary
endpoints and, since many trials do have normally distributed endpoints, in
this way we hope further to bridge the gap between MABP theory and clini-
cal trial practice. The second objective is to identify and address issues that
may limit the use in pratice of the MABP-based designs considered in this
paper. Specifically, we consider in detail the level of bias and type I error
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rates observed under this setting and further suggest appropriate procedures
to control them. Results are illustrated by simulations in the context of a
currently ongoing clinical trial: TAILoR trial, described in [25].
The structure of this paper is as follows: In Section 2 an overview of
the general MABP with a continuous state variable and its solution for the
special case of a normally distributed reward is provided together with an
adaptive patient allocation rule based on it. Then, Section 3 presents some
simulations of two-armed and multi-armed trials implementing bandit strate-
gies for normally distributed endpoints and comparing them to alternative
trial designs. Section 4 concludes with a discussion of our findings and lines
of further research.
2 The classic Bayesian multi-armed bandit prob-
lem with a continuous state variable and known
variance
Let K ∈ N and consider a collection {Xk,t : k = 0, 1, . . . , K, t = 0, 1, 2, . . .}
of independent (real-valued) random variables, where for each fixed k the
distributions of Xk,0, Xk,1, Xk,2, . . . are identical and parametrised by some
unknown θk ∈ Rp. At each time t = 0, 1, 2, . . . , T − 1 we obtain a reward by
choosing some distribution k ∈ {0, . . . , K} and sampling from Xk,t. In the
context of a clinical trial, this corresponds to choosing the treatment allo-
cation of the tth patient, and Xk,t corresponds to the endpoint observation
for patient t on treatment k. In order to incorporate the adaptive learning
element into the model, we take a Bayesian viewpoint and assume Θk is
a random variable taking the value θk. We assign Θk a prior distribution
pi
(0)
k , which is assumed to be a density function with respect to Lebesgue
measure. By Bayes’ Theorem, the posterior density of Θk, having observed
values xk,i1 , . . . xk,in in n independent samples from Xk,i1 , . . . , Xk,in after hav-
ing treated t patients, is
pi
(t)
k (θ |xk,i1 , . . . , xk,in ) ∝ pi(0)k (θ)
n∏
j=1
fk(xk,ij |θ),
where fk(·|θ) is the density of Xk,t (with respect to Lebesgue measure) [14]
. Note that we have used the subscript ij (for j = 1, . . . , n) to emphasize
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that the sample of n observations from distribution k is a subset of the total
number of sampling observations possible at time t.
Formally, the classic Bayesian MABP within this general setting is defined
by formulating a Markov decision process as follows. Consider each distribu-
tion (or arm) k as a Markov process Bk with a Borel state space (Ek, Ek), by
taking the state ξk(t) ∈ Ek of Bk at time t to be the value x˜ of some chosen
sufficient statistic X˜k for the posterior density of Θk, and updating the state
every time we sample from this arm. At each time t = 0, . . . , T −1 a decision
variable ak,t ∈ {0, 1} is chosen for process Bk for each 0 ≤ k ≤ K, such that
exactly one arm receives action 1 (is sampled) and all others receive action 0
(their posterior density remains frozen). If ak,t = 0 then Bk is frozen (and so
is its associated value for the sufficient statistics), thus ξk(t+ 1) = ξk(t) with
probability 1. If ak,t = 1 then ξk evolves according to a Markovian transition
kernel Pk, i.e. for any A ∈ Ek and x˜0, x˜1, . . . , x˜t−1, x˜ ∈ Ek we have
P[ξk(t+ 1) ∈ A|ξk(t) = x˜, ξk(t− 1) = x˜t−1, . . . , ξk(0) = x˜0] = P[ξk(t+ 1) ∈ A|ξk(t) = x˜]
= Pk(x˜, A).
The transition kernel Pk is a density pk (with respect to Lebesgue measure
on R):
pk(x˜, x˜ ? y) =
ˆ
Rp
fk(y|θ)pi(t)k (θ|x˜)dθ, (2.1)
where x˜ ? y denotes the updated value of X˜k if y is the next value sampled.
If the processBk is sampled at time t we earn the random rewardRk(ξk(t), ξk(t+
1)), where Rk : E2k → R is the reward function of Bk. In the classic MABP
this function is given by Rk(x˜, x˜ ? y) = y, i.e. the value of Rk is the value
taken by Xk,t. We define rk : Ek → R as the expected reward from the
process in a given state [18], given by
rk(x˜) = E [Rk(ξk(t), ξk(t+ 1)) |ξk(t) = x˜ ]
= E
[
Xk,t
∣∣∣X˜k = x˜] . (2.2)
Let E = E0 × · · · × EK be the joint state space of the MABP, and
ξ(t) = (ξ0(t), . . . , ξK(t)) ∈ E the joint state vector of the MABP at time
t. Let Π be the set of all feasible sampling policies, i.e. those in which the
decision at time t depends only on past information and only sample one
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arm (or distribution) at a time. Writing apik,t for the sequence of sampling
decisions chosen by policy pi, the value function for the classic MABP with
a continuous state variable is
V ∗d (ξ) = sup
pi∈Π
E
[
K∑
k=0
T−1∑
t=0
dtrk(ξk(t))a
pi
k,t
∣∣∣∣∣ ξ(0) = ξ
]
. (2.3)
Thus, the MABP is the problem of finding a policy pi ∈ Π which maximises
the value of the expected total discounted reward of the sampling process.
Notice that d is a discount factor (i.e. 0 ≤ d < 1) introduced for reasons of
tractability, so that the infinite horizon problem (T =∞) can be considered.
One approach to solve the MABP in (2.3) would be via the dynamic
programming equation
V ∗d (ξ) = max
i∈{0,...,K}
ri(ξi) + d
ˆ
Ei
Pi(ξi, dy)R(ξ1, . . . , ξi−1, y, ξi+1, . . . , ξK)
 .
(2.4)
Standard theory on Markov processes ensures that there is an optimal solu-
tion to (2.3), and approximations to it may be obtained using value iteration
on (2.4) [9], but such an approach is computationally expensive, exploding
with the truncation horizon T even for a small number of arms K > 3 [23].
For the infinite horizon MABP Gittins and Jones [7] provided a theorem by
which there exists a function ν = ν(Bk, x˜k) such that at any time the optimal
strategy is to sample the process which has the highest value of ν. There is
a clear computational advantage to this approach: if we can compute a grid
of values of ν for each bandit process, then the policy can be followed any
number of times by looking up values of ν for each process at each decision
time. Several proofs of the Index Theorem are given in [9]. Gittins and Jones
referred to ν as a dynamic allocation index, but this is now known widely as
the Gittins index.
In the case where the MABP state space is discrete, as in the Bernoulli
case, values of ν can be looked up from a matrix. With a continuous state
space it is less clear that all the necessary calculations can be performed in
advance. However, in most useful cases, including the normally distributed
case, the function ν(Bk, x˜k) is a linear function of Bk and x˜k under some
discrete boundary conditions; the discrete part can thus be calculated in
advance as a matrix of values [9].
6
For the finite horizon problem, which is the relevant case in the clinical
trial context, [23] suggested an index-based solution to the finite horizon
MABP based on the Whittle index [26]. However, the Whittle index is
omitted from the studies in this paper since in most trials its performance
was near identical to that of the Gittins index (calibrated through the choice
of the discount factor d) which further has a lower computational cost.
2.1 The Gittins index as a Bayesian adaptive patient al-
location rule for the normally distributed endpoint
(with known variance)
In this paper we consider clinical trials for which the endpoint of each treat-
ment arm k is assumed to be normally distributed with unknown mean µk
and known variance σ2k. We therefore consider the rewards from arm k to be
an independent identically distributed (iid) sequence Xk,t
iid∼ N(µk;σ2k), and
µk is given a prior distribution pi
(0)
k , which we will take to be the improper
uniform distribution on the whole real line. The uniform prior distribu-
tion assumption will allow us to isolate the effect on patient welfare and
other relevant statistical properties of the MAB adaptive design alone, i.e.,
without the use of prior (historical) data. Let f(·|µ;σ2) denote the den-
sity of a N(µ;σ2) distribution. If we have observed n independent samples
xk,i1 , . . . , xk,in from Xk,i1 , . . . , Xk,in , then, writing xk,n =
1
n
∑n
j=1 xk,ij for the
sample mean, by Bayes’ Theorem the posterior density of µk at time t is
pi
(t)
k (µk|xk,i1 , . . . , xk,in) ∼ N
(
xk,n;
σ2k
n
)
. A sufficient statistic for the posterior
distribution of µk is (xk,n, n), thus the state vector of process Bk in this case
will be (x, n) where n is the number of observations so far sampled from arm
k after having treated t patients, and x¯ is the mean of these observations.
As explained in [9] for the MABP with normally distributed rewards with
known variance, the indices ν(x, n;σ2k, d) can be written as follows
ν(x, n;σ2k, d) = x+ σkν(0, n; 1, d). (2.5)
Therefore, to implement the Gittins index policy at very low computa-
tional cost it suffices to calculate in advance the values of ν(0, n; 1, d). This
can be done to a good accuracy using value iteration on (2.4) in the case of
the two-armed bandit calibration setup. Details are given in [2, pp. 131-162]
and [9, Chapters 7 & 8]. Computational results for this case were first com-
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puted in [12]. The values of the indices ν(0, n; 1, d) used in this paper have
been interpolated from the tables printed in [9, pp. 261-262].
Figure 2.1 shows the values of the indices ν(0, n; 1, d) for a range of dis-
count factors d. In [10], the learning component of the index is defined as the
difference between the index value and the expected immediate reward, which
for this MABP corresponds to the reward from sampling an arm with poste-
rior mean x from previous samples, i.e. simply x. Therefore, σkν(0, n; 1, d)
can be interpreted as a measure of the learning reward associated with con-
tinuing sampling an arm which has already been sampled n times. Figure 2.1
illustrates clearly that ν(0, n; 1, d) increases with d, since a larger discount
factor puts greater value on future rewards and increases the value of learn-
ing. However, for any choice of d, the value of learning drops very quickly
as n increases; in the limit as n tends to infinity, the value of learning tends
to 0 and the sample mean converges by the Law of Large Numbers, so the
index tends to the true value of the parameter µk.
The Gittins index solution for the case of both µk and σk being unknown
exists and is similar to that in (2.5). The difference is that the model requires
a joint prior distribution on both parameters and the known variances in (2.5)
are replaced by sample variances.
2.2 Some considerations specific to the use of bandit
strategies in a clinical trial context
In [23] simulation results comparing a number of alternative patient allo-
cation rules to index-based solutions for trial scenarios with dichotomous
endpoints were provided. The authors conclude that, alongside the clear ad-
vantages, there are a number of limitations to the use of the Gittins index as
an allocation mechanism for clinical trials. Some of these disadvantages are
still going to be an issue in the normally distributed case. The endpoint needs
to be immediately observable so that index rules can be applied. This means
that a patient in the trial cannot be treated until all previous outcomes have
been observed. This is a strong limitation that affects all adaptive designs in
general and not only MAB-led designs. In practice, this limits the speed at
which new patients can be recruited to the trial; however, this may be less
problematic in a rare disease context, where the rate of patient recruitment
is likely to be slow already. Applying the adaptive algorithms in batches
of patients rather than patient after patient is a way of acknowledging and
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partially addressing this issue [17, 24].
Another limitation still present is that the allocation of treatments in
a Gittins index-based design is highly deterministic, which can lead to the
introduction of different sources of bias. As explained in [3], randomisation
prevents the trial results from being influenced by “secular trends in the pop-
ulation’s health and our ability to measure it, in the quality of recruits to
the trial and in the virulence of a disease.” In trials where the clinician
can influence which patient receives the next treatment, so-called selection
bias (the ability of the experimenter to predict which treatment will be allo-
cated next) can influence the results. These extrinsic bias effects are absent
from the simulations next presented and from those in [23], but could have a
significant impact when deterministic rules are used on trials with real pop-
ulations. Recent work [24] addresses this particular limitation proposing a
simple modification of the Gittins index rule for the Bernoulli case that is
randomised. Notice that the lack of randomisation of the resulting patient
allocations is a limitation shared with most bandit-based algorithms, even
those that introduce random terms in their definitions as e.g., [1] or [11].
For other limitations and also for the patient-benefit advantages of index-
based designs reported in [23], the magnitude or even their existence requires
careful consideration. This is the case for the possibility of introducing intrin-
sic sources of bias. Response-adaptive trials in general can result in biased
estimate of a treatment’s outcomes. For example, in a two-arm trial scenario
[23] found that the use of the Gittins index introduced a significant nega-
tive bias in the estimate of treatment outcomes; the magnitude of the bias
is greatest for inferior treatments (since they are more likely to be dropped
early in the trial) and the treatment effects are likely to be overestimated.
Similar considerations apply with respect to the resulting rates of type I error
(a false positive result, i.e. incorrectly rejecting the null hypothesis H0) and
of type II error (failing to detect that an experimental treatment is effective,
i.e. incorrectly accepting H0). [23] reported that the index-based designs
achieved a level of statistical power that was far below the level of an RCT
with the same number of patients T and also that control of the type I error
rate required adjusting the statistical test to correct for its conservativeness
(i.e. moderate deflation).
An important contribution of this paper is to assess the extent to which
further considerations different from the ones mentioned above apply to the
normally distributed endpoint. In particular, assessing how important the
bias and statistical error levels are in the normally distributed case, and
9
suggesting how to control for the type I error rate at a desired level, are two
of the main contributions of this work.
3 Simulation studies
In this section we evaluate the performance of a range of patient allocation
rules in a clinical trial context, including bandit-based solutions using the
Gittins index. As a case study for simulations we shall use a generalisation
of the currently ongoing TelmisArtan and InsuLin Resistance in HIV trial
(TAILoR trial), which is described and also used as a case study in [25]. See
also [15] for discussion of the design of the TAILoR trial.
The TAILoR trial is a one-sided test ofK experimental treatments against
a control treatment (i.e. testing for superiority). Treatment k is assumed to
have endpoint outcomes Xk,t
iid∼ N(µk;σ2), for k = 0, 1, . . . , K (where k = 0
is the control treatment), and σ2 is known and common to all treatments.
Setting δk = µk − µ0, the global null hypothesis is H0,G : δ1, . . . , δK ≤ 0 and
the alternative hypotheses are H1,k : δk > 0, 1 ≤ k ≤ K.
We focus on the following: statistical power (1−β); type-I error rate (α);
expected proportion of patients in the trial assigned to the best treatment
(Ep∗); the Expected Outcome (EO) defined as the mean patient outcome
across the trial realisations; and, for the two-arm case, bias in the maximum
likelihood estimate of treatment effect associated with each decision rule.
For testing these hypotheses we shall use the following test statistics
Zk =
Xk −X0
σ
√
1
nk
+ 1
n0
, k = 1, . . . , K,
where nk is the number of sample observations taken from arm k andXk is the
sample mean of arm k. Under the assumption that the nk’s are independent
and identically distributed samples, these k test statistics will follow a normal
distribution with mean δk/
(
σ
√
1
nk
+ 1
n0
)
and variance 1. In the case of a two-
arm trial with one experimental treatment to be tested against a control,
this simplifies to the case of a standard z-test using a univariate normal
distribution. For the multi-armed case we will consider the joint distribution
of Z1, . . . , Zk and use a critical value Cα that controls the Family-Wise type
I Error Rate (FWER), defined as P [{rejectH0,G}|H0,G], within a specified
level α ∈ (0, 1).
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For each scenario we set the size of the trial T to ensure that an RCT
with equal randomisation achieves a specified power (1 − β) to detect a
specified effective treatment difference δ(1) between each arm and the control,
while controlling the FWER within α. Because we are interested in the
marginal type II error rate in a single test, rather than a family-wise error
rate, we consider the marginal distributions rather than a joint distribution
to determine a required sample size per arm for an RCT. Following this
rationale it can be computed that the total required size of the RCT trial
(i.e. across all arms) is
T =
K∑
k=0
nk = (K + 1)
(
2σ2(Cα + zβ)
2
(δ(1))
2
)
, (3.1)
where zβ is the 100(1−β)th-percentile of a standard N(0, 1) distribution. See
appendix I for details of how Cα is determined and e.g., [28] for a review of
sample size calculation in RCTs.
Following [25], we shall assume the variance in the outcomes is σ2 = 1,
and specify the treatment difference to be detected as δ(1) = 0.545 (chosen
such that the probability of a patient given a treatment k with δk = δ(1)
having a better outcome than a patient on the control treatment is 0.65).
We will consider the usual error rates of α = 0.05 and β = 0.10.
In every scenario we consider the following patient allocation procedures:
• Fixed Randomised (FR): for each patient, treatments are allocated ran-
domly with fixed probability 1
K+1
across all treatments;
• Thompson Sampling (TS)[21]: for each patient, treatments are allo-
cated randomly, where the probability pik,t of allocating treatment k to
patient t is proportional to the posterior probability that treatment k
is the best, i.e.
pik,t =
P
[
max
i
µi = µk |Xk,t
]c
∑K
l=0 P
[
max
i
µi = µl |Xl,t
]c
where c is a tuning parameter defined as t
2T
introduced to stabilise the
resulting allocation probabilities [20]. The probabilities in the fraction
are estimated by simulation at each t;
11
• Upper Confidence Bound (UCB): for the first K + 1 patients, patient
t is allocated treatment k = t− 1; each patient t > K + 1 is allocated
the treatment k with the highest value of the index xk + σ
√
2lnt
nk
, as
proposed in [13] and [1];
• Kullback-Leibler Upper Confidence Bound (KLU): for the first K + 1
patients, patient t is allocated treatment k = t − 1; each patient t >
K + 1 is allocated the treatment k with the highest value of the index
xk + σ
√
2(lnt+3(ln lnt))
nk
. This variant of UCB was shown in [6] to have
improved asymptotic regret bounds compared to UCB;
• Current Belief (CB): the next patient is allocated the treatment with
the highest posterior mean xk;
• Gittins Index (GI): the next patient is allocated the treatment with the
highest value of the Gittins Index ν(xk, nk;σ2, d), where d is the value
of the discount factor;
• Randomised Gittins Index (RGI): as first suggested in [11], the next
patient is allocated the treatment with the highest value of the semi-
randomised index ν(xk, nk;σ2, d)+K+1nk Yt, where Yt is a random variable
sampled from the exponential distribution with mean 1
K+1
(this choice
of randomisation element is the same as that used by [23]);
• Randomised Belief Index (RBI): as first suggested in [4], the next pa-
tient is allocated the treatment with the highest value of the semi-
randomised index xk + K+1nk Yt, where Yt is a random variable sampled
from the exponential distribution with mean 1
K+1
.
For the multi-armed scenarios we have additionally considered the fol-
lowing rules:
• Trippa et al. Procedure (TP): for each patient, treatments are allocated
randomly, where the probability pik,t of allocating treatment k to patient
t is defined by
pik,t =
pik,t∑K
l=0 pil,t
,
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where
pik,t =

P [µk > µ0 |xk,t−1]γt∑
l≥1 P [µl > µ0 |xl,t−1]γt
, k ≥ 1
1
K
exp
[
max
k=1,...,K
[nk,t − n0,t]ηt
]
, k = 0,
in these simulations we have considered γt = 3
(
t
T
)1.75 and ηt = 0.25 ( tT ),
as in [22]. Note that this procedure is only considered for multi-arm
trials because by design its allocation to the control arm will closely
follow that of the best experimental arm.
• Controlled Gittins (CG): each patient is randomly assigned the control
treatment with (fixed) probability 1
K
. If the patient is not randomly
assigned to the control group in this way, then she is assigned to the
treatment with the greatest Gittins index. Although CG deviates from
the optimality of GI, it was still found in [23] to offer a significant
improvement in patient welfare over FR; moreover, it largely combatted
the issue of reduced power. In fact, when there existed a clear superior
treatment among the K arms it was found to achieve even higher power
than FR.
• Controlled UCB (CUC): a variant of UCB with the control allocation
protected as in CG above.
In all scenarios we also include “batched” versions of the Bayesian rules
in which the allocation probabilities are updated after a block of b
patients are treated instead of after every patient. This idea was im-
plemented in [17, 24] as a means of overcoming the practical limita-
tions imposed by the assumption of immediate outcome observability
of these algorithms. Their inclusion is intended to more closely repli-
cate the constraints of a real life clinical trial without fully sequential
design. Specifically, we consider:
• Batched Thompson Sampling (TSB) and Batched Trippa et al. Proce-
dure (TPB): as per TS and TP above, but the allocation probabilities
pik,t are only updated after every 20 patients. The size of the batch
(b = 20) was chosen to illustrate the effects of a moderate delay in
relation to the first two trial sizes considered in this paper and a more
severe delay for the trial size reflecting a rare disease scenario. Note
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that none of the trial sizes assumed are exactly divided by b = 20. This
leaves a few remaining patients which are allocated using the allocation
probabilities resulting after observing the outcomes of last block.
In every scenario considered and for every procedure we assumed that the
prior for the µk parameters is the improper uniform distribution on the whole
real line. Notice that a fully Bayesian approach to the design could make
use of historical data existing before the trial through appropriate choice of
the prior distribution. In this paper we have chosen to use an uninformative
prior to make results comparable to the case study in [25] and to isolate the
effects of the adaptive designs in the different performance measures.
For the rules that are based on the Gittins index values there is an obvious
ethical concern around the choice of a discounting factor when calculating
the indices: clearly current and future patients’ wellbeing should be valued
equally. So for scenarios with large sample sizes we will take d close to 1,
usually d = 0.995. In the case of a rare disease, if it is known that not more
than N patients will ever be treated, the value of d could be chosen so that
dN ≈ 0, to ensure that the possibility of treating patients beyond N has
little impact on current decisions. By doing this the current estimation of
the patient population could be used to indirectly affect the choice of trial
design. In all trial designs and in all simulations, ties among index values are
broken randomly.
3.1 Two-arm trial
We first simulate the TAILoR trial with one experimental arm to be com-
pared with a control treatment, i.e. K = 1. The trial is implemented under
H0 with δ1 = µ0 = µ1 = 0 and under H1 with µ0 = 0, µ1 = 0.545 (i.e.
δ1 = 0.545). In both scenarios the common variance is σ2 = 1 and d = 0.995.
The sample size considered is of T = 116 patients. This size ensures a 5%
type I error rate (using Cα = 1.645 as a critical value) and(1 − β) = 90%
power to detect a difference of δ(1) = 0.545 through a FR design.
3.1.1 Type I error control for adaptive designs
For the adaptive allocation mechanisms, including the Gittins index-based,
the use of a critical value of Cα = 1.645 is found in simulations to generate
a type I error rate inflated above 5%. This is in stark difference to the type
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I error deflation reported in [23, 24]. We will next explain this phenomenon
in detail in terms of the GI rule but a similar logic applies for other adaptive
rules.
In each realisation of the trial, if one arm performs badly early on and
is dropped (or allocated with a very low probability), then the sample mean
from this arm will not have a chance to regress upwards to the mean (or do
so more slowly), being therefore negatively biased. Figure 3.1 illustrates this
in a typical GI trial run under H0, displaying the posterior mean xk,t of the
outcomes for each treatment arm k after t patients have been allocated that
arm. In this example, the control arm k = 0 performs badly early on in the
trial, so is dropped with just n0 = 19 patients, leaving the trial’s estimate of
this treatment’s outcomes negatively biased. The experimental arm performs
better early on, so is continued and regresses to its mean; thus the trial’s final
estimate of this treatment’s effect is close to the true value of 0. The result is
that the test statistic takes the value 1.81 > 1.645, so a hypothesis test using
the normal cut-off value of 1.645 would generate a type I error, incorrectly
concluding the superiority of the experimental arm.
In order to choose a more suitable critical value for the hypothesis tests
when using adaptive designs, we estimate the distribution of the test statistic
Z under each trial design by a Monte Carlo simulation with 104 repeats of
the trial under H0. Figure 3.2 shows the observed empirical distributions of
Z for the GI trials, implemented under H0 and under H1. In each case, as
well as a histogram of the observed empirical distribution, also displayed is a
curve of the standard normal distribution which the test statistic is expected
to follow in a FR trial, for comparison.
In Figure 3.2a we see that, in the GI trial under H0, the distribution of
the test statistic is starkly different from a normal distribution. The sample
standard deviation of 1.37 is much greater than the standard deviation of 1.00
in the FR case, and the heavier tails than a normal distribution correspond
to an inflated type I error rate when hypothesis testing is carried out with
the normal critical value of 1.645. Notice that because both left and right
tails are heavier than the normal tails, the inflation of type I error rate when
testing hypotheses at the normal cut-off value would be even greater in a
two-tailed test.
The empirical cumulative distribution function evaluated at 1.645 is FˆGI,H0(1.645) =
0.89, indicating that we might expect a type I error rate of 11% if hypothesis
testing was carried out with this critical value. Instead, the empirical 95th-
percentile of the distribution is C0.05 = Fˆ−1GI,H0(0.95) = 1.951, marked on the
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histogram by a vertical dotted line. We will therefore use this as the critical
value for hypothesis testing in the GI trials to control the type I error rate
within 5%.
Notice that the two peaks in the frequency density arise from the two sit-
uations in which the estimate of one arm’s outcomes is negatively biased, and
the other is unbiased: the right-hand peak corresponds to an incorrect con-
clusion that the experimental treatment is superior to the control treatment
(the situation illustrated in Figure 3.1), and the left-hand peak corresponds
to an incorrect conclusion of the opposite.
Figure 3.2b illustrates that if the GI trial is implemented under H1 the
bimodality of the distribution of the test statistic is greatly reduced, but still
present to some extent. FˆGI,H1(1.951) = 0.77, i.e. 77% of the distribution
still lies to the left of the empirical critical value of 1.951, marked by a vertical
dotted line; thus we expect to observe greatly reduced power of around 23% in
the GI trials. The (small) left-hand peak has a weight of FˆGI,H1(−0.5) = 5%,
indicating that in 5% of trials the superior arm is dropped early on due to
poor initial performance, and the trial has ended up favouring the wrong
arm.
Following the same procedure, 95th-percentiles of the test statistic distri-
bution are estimated for the other adaptive trial designs. Histograms for the
distributions of the test statistics in the other trial designs are displayed in
Appendix II in Figure 4.1. Notably, TS, RGI, UCB and KLU are the only
ones of the adaptive designs which appear unimodal in both scenarios. The
unimodality of TS, RGI, UCB and KLU under H1 (Figure 4.1b) indicates
that, in almost all realisations of these trials under H1, the trial is correctly
favouring the superior experimental arm by the end of the trial.
3.1.2 Results and discussion
We now present results of 104 repetitions of each trial design using the es-
timated values described before as a priori critical values. The results of
the simulation are displayed in Table 1. Ep∗ under H0 is computed as the
proportion of patients receiving the control treatment, and under H1 as the
proportion of patients receiving the experimental treatment. The (s.d.) val-
ues are the standard deviations associated with each measurement. The
Upper Bound (UB) row displays a theoretical optimum for each measure-
ment based on a design which assigns every patient to the best treatment
(i.e. p∗ = 1) in every trial.
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H0 : µ0 = µ1 = 0 H1 : µ0 = 0, µ1 = 0.545
Cα α Ep∗ (s.d.) EO (s.d.) (1− β) Ep∗ (s.d.) EO (s.d.)
FR 1.645 0.0510 0.4997 (0.05) -0.0001 (0.09) 0.8996 0.4997 (0.05) 0.2718 (0.10)
(Adaptive TS 1.701 0.0528 0.5006 (0.11) 0.0003 (0.09) 0.8723 0.7317 (0.10) 0.3997 (0.11)
random) TSB 1.676 0.0519 0.4994 (0.10) -0.0001 (0.09) 0.8824 0.6962 (0.09) 0.3816 (0.11)
(Semi-random RBI 1.998 0.0509 0.5041 (0.37) -0.0001 (0.09) 0.3493 0.8891 (0.17) 0.4845 (0.13)
index-based) RGI 1.941 0.0487 0.5005 (0.27) 0.0000 (0.09) 0.5494 0.8764 (0.09) 0.4765 (0.10)
(Index-based)
UCB 2.068 0.0508 0.5050 (0.24) 0.0012 (0.09) 0.5575 0.8697 (0.10) 0.4734 (0.11)
KLU 1.867 0.0481 0.5021 (0.17) -0.0001 (0.09) 0.7777 0.8225 (0.08) 0.4489 (0.10)
CB 1.782 0.0420 0.4918 (0.48) 0.0007 (0.09) 0.1724 0.7624 (0.40) 0.4139 (0.24)
GI 1.951 0.0437 0.5006 (0.38) -0.0010 (0.09) 0.2373 0.8786 (0.23) 0.4796 (0.16)
UB 0.0000 (0.09) 1.0000 (0.00) 0.5450 (0.09)
Table 1: Comparison in 104 trial replicates of operating characteristics of different two-arm
trial designs of size T = 116, under both hypotheses. Cα : critical value used in hypothesis
testing; α: type I error rate; Ep∗: mean proportion of trial patients assigned the best
treatment; (s.d.): standard deviation for each measurement; EO: mean patient outcome;
(1 − β): statistical power. UB: theoretical upper bound from assigning all patients best
treatment.
All the adaptive rules achieve better patient welfare than the FR design
under H1. In this scenario RBI, RGI, UCB and GI all perform similarly well
in patient welfare, with EO values between 0.47 and 0.48, the closest values
to the theoretical upper bound of 0.545. Note that this contrasts with the
findings in [23] for the Bernoulli case, where GI was found to achieve much
better patient welfare than either of the semi-randomised designs. However,
the results for these rules are in line with their poorer performance in terms of
power when compared to the findings in [23]. The TS trial is outperformed by
the other adaptive designs in terms of patient welfare; this is explained by the
tuning parameter c in the TS mechanism which stabilises the randomisation
probabilities.
The high standard deviations in p∗ for all the adaptive designs under H0
indicate that p∗ has a broad distribution across the realisations of the trial,
so the trials are not consistent and are frequently unbalanced. The standard
deviation of 0.48 for CB is close to the limiting case where, in each trial,
p∗ ∼ Bernoulli(1
2
), i.e. all patients within a trial are assigned to the same
treatment, which would give a standard deviation of
√
1
2
(1− 1
2
) = 0.50 in
p∗ across the trials. This indicates that most trials under CB (and to some
extent also GI and RBI) are highly unbalanced, with one arm being dropped
early on and most patients receiving the same treatment).
Under H1, the high standard deviation in p∗ under GI arises from the
bimodality observed in Figure 3.2b: in a small proportion of realisations
17
of the trial, the control arm is incorrectly favoured and p∗ < 1/2. The lower
standard deviation in p∗ for RGI confirms that RGI trials are more consistent
in correctly favouring the superior treatment arm. As expected, the GI trial
has greatly reduced statistical power (just 24%) compared to the value of
90% achieved by the FR trial. Reduced power is also evident in the other
trial designs (c.f. Figure 4.1); CB has the lowest power (17%).
Note that UCB outperforms KLU in patient welfare, but KLU offers
significantly higher power (78%) than UCB (56%). Interestingly, despite the
improved regret bounds for KLU proved in [6] KLU only begins to dominate
UCB under both power and patient benefit when the number of patients is
very large. Nevertheless, KLU seems to achieve the best compromise between
patient welfare and statistical inference out of other modifications to the UCB
algorithm designed to improve regret bounds reviewed for this paper, with
power of 78% and EO of 0.45 (only slightly below the 0.48 achieved by GI).
The low standard deviation of 0.10 in expected outcome indicates that the
welfare benefit is more consistent than in the GI trial.
The results for the batched TS (TSB) illustrate the effects of a blocked
implementation of the algorithm to deal with a moderate delay: a marginal
increase in power and a considerable decrease of the patient welfare benefits.
However, the patient benefit advantages of TSB over FR are considerably
large even if assuming a moderate delay in patient recruitment.
3.1.3 Bias in treatment effect estimates
Figure 3.3 shows the mean (across the trial realisations) of the bias (x(t)k −µk)
in the estimated outcome of each treatment after a total of t patients have
been treated across both arms in the trial, under each scenario. Figures 3.3a
and 3.3b show the GI design introducing a negative bias into estimates of both
treatment’s effects; within each trial realisation this bias will be restricted
to one of the two arms, corresponding to the two modes of the test statistic
distribution in Figure 3.2a. In all scenarios, the deterministic designs GI and
CB exhibit larger bias than the semi-randomised designs RBI and RGI.
3.2 Four-arm trial scenario
This scenario uses the TAILoR trial but now considers K = 3 experimental
treatments to be compared with a control treatment. To achieve a type I
error rate of 5%, the critical value is Cα = 2.0621 for the FR trials. Once
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again we take σ2 = 1, and we assume a trial size is of T = 302 patients since
this is the total required trial size for FR to achieve (1 − β) = 90% power
to detect a difference of δ(1) = 0.545 in treatment outcome. The trial is
implemented under H0 with µ0 = µ1 = µ2 = µ3 = 0 and under H1 with µ0 =
0, µ1 = µ2 = 0.178, µ3 = 0.545. These values are chosen to give the Least
Favourable Configuration (LFC) for the trial, with µ1 = µ2 = δ(0) and µ3 =
δ(1), where, as [25] explain: “δ(1) is a prespecified clinically relevant effect, and
δ(0) is some threshold below which a treatment is considered uninteresting.
The configuration is called least favourable as it minimises the probability of
recommending a treatment with effect greater than or equal to δ(1) amongst
all configurations where at least one treatment has a treatment effect of δ(1)
or higher and no treatment effects lie in the interval (δ(0), δ(1)).” Following
[25], δ(0) = 0.178 is chosen so that the probability of a patient on a treatment
with this treatment effect achieving a better outcome than a patient on the
control treatment is 0.55 and the corresponding probability for δ(1) = 0.545
is 0.65.
We will compare all the trial designs, including now the Controlled Gittins
(CG) design, in which each patient is allocated the control treatment with
probability 1
K+1
= 0.25, and otherwise allocated the drug with the highest
value of the Gittins Index. We compare CG design against similar proce-
dures: the Trippa Procedure (TP) and Controlled UCB (CUC) designs. We
also include the Batched Trippa Procedure (TPB) to assess the effects of de-
lays in outcome observability. The Gittins Indices used are again based on
discount factor d = 0.995. To calculate critical values for the trial designs
other than FR, Monte Carlo simulations were run as explained in section
3.1.1. Critical values are found by calculating the empirical 95th-percentile
of the distribution of Zmax := max
j=1,2,3
Zj, in order to control the FWER. Trial
simulations are then run using the computed quantiles as critical values; for
each design the trial is run 104 times. Results are displayed in Table 2.
As in the two-arm scenario, all the adaptive rules outperform the FR
design under H1 in terms of patient welfare, although TP only improves
marginally over FR in this case. The greatest EO values are achieved by
RGI, RBI, UCB and GI, but these designs and CB exhibit a greatly reduced
power level compared with FR, rendering them less useful as trial designs
from a frequentist point of view. In particular, CB, which is essentially the
simplest myopic approach, exhibits the worst performance in terms of power
and variability. As in the two arm trial, KLU achieves considerably greater
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H0 : µ0 = µ1 = µ2 = µ4 = 0 H1 : µ0 = 0, µ1 = µ2 = 0.178, µ3 = 0.545
Cα α Ep∗ (s.d.) EO (s.d.) (1− β) Ep∗ (s.d.) EO (s.d.)
FR 2.062 0.0534 0.2493 (0.02) 0.0006 (0.06) 0.8982 0.2502 (0.02) 0.2252 (0.06)
TS 2.198 0.0476 0.2504 (0.08) -0.0001 (0.06) 0.8751 0.4997 (0.10) 0.3394 (0.07)
TSB 2.103 0.0514 0.2497 (0.07) -0.0001 (0.06) 0.8989 0.4794 (0.10) 0.3314 (0.07)
RBI 2.041 0.0519 0.2469 (0.27) 0.0002 (0.06) 0.3608 0.7917 (0.22) 0.4624 (0.10)
RGI 2.070 0.0499 0.2479 (0.18) -0.0006 (0.06) 0.6309 0.7603 (0.12) 0.4462 (0.07)
UCB 2.223 0.0500 0.2507 (0.13) 0.0001 (0.06) 0.7333 0.7028 (0.12) 0.4238 (0.08)
KLU 2.154 0.0434 0.2502 (0.09) -0.0002 (0.06) 0.8718 0.6068 (0.10) 0.3848 (0.07)
CB 1.691 0.0524 0.2468 (0.41) 0.0008 (0.06) 0.1075 0.4941 (0.49) 0.3438 (0.20)
GI 1.955 0.0486 0.2457 (0.28) -0.0008 (0.06) 0.2264 0.7743 (0.29) 0.4552 (0.13)
CG 1.923 0.0405 0.4577 (0.21) -0.0006 (0.06) 0.8667 0.5681 (0.22) 0.3392 (0.10)
CUC 1.934 0.0572 0.3362 (0.09) 0.0007 (0.06) 0.9599 0.5357 (0.10) 0.3277 (0.07)
TP 2.027 0.0498 0.2593 (0.02) -0.0010 (0.06) 0.9418 0.3095 (0.06) 0.2462 (0.06)
TPB 2.027 0.0479 0.2488 (0.02) 0.0003 (0.06) 0.9342 0.3082 (0.06) 0.2476 (0.06)
UB 0.0000 (0.06) 1.0000 (0.00) 0.5450 (0.06)
Table 2: Comparison in 104 trial replicates of operating characteristics of different four-arm
trial designs of size T = 302, under both hypotheses. Cα : critical value used in hypothesis
testing; α: type I error rate; Ep∗: mean proportion of patients in a trial assigned the best
treatment; (s.d.): standard deviation for each measurement; EO: mean patient outcome;
(1 − β): statistical power. UB: theoretical upper bound from assigning all patients best
treatment.
power than UCB and the welfare benefit is only slightly reduced, offering a
very good compromise between the two conflictive objectives.
As in the two-armed case TSB (90%) achieves marginally higher power
than TS (88%) in return for slightly lower patient welfare (EO of 0.33 com-
pared to 0.34). Conversely, TPB results in a slightly reduced power than TP
while the patient wlefare is practically identical. In both cases, the difference
caused by the moderate “batching” of patients’ outcomes is small, indicat-
ing that these adaptive designs could offer patient benefit advantages even if
applied without a fully sequential design.
As expected, the family of “protected control” designs: TP, CG and CUC,
offer a compromise between learning (power) and earning (patient welfare).
Whilst CG does not perform as well as GI in patient welfare, its EO value
of 0.3392 is still a significant improvement on FR’s 0.2252, and the 87%
power attained by CG is greater than that of many of the other adaptive
designs, and only marginally lower than FR’s 90%. CUC compares similarly
to UCB and dominates over TP by offering a significantly increased patient
welfare with a slight increase in power over TP. Just as found in [23] for the
Bernoulli case, fixing the control allocation in this way is a simple heuristic
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modification of adaptive allocation rules that results in good trial designs in
terms of both patient welfare and frequentist operating characteristics.
Figure 3.4 shows the bias in the estimates of treatment outcomes in this
scenario, for the control treatment and the best experimental treatment (arm
3). For the designs which were included in the two-arm simulation, the results
here are similar. CG significantly lowers the bias in the estimates of control
treatment outcomes, but it does not improve the issue of negatively biased
estimates of unselected experimental treatment outcomes, where it performs
almost identically to the original GI.
3.3 Four-arm rare disease trial scenario
The final simulation scenario is the same as in section 3.2 but with the trial
size reduced to T = 64 to imitate a rare disease setting where the number of
patients who can be recruited is limited. Notice that for T = 64 the FR trial
will achieve a power of 30% while controlling the FWER within 5%. The
same critical values are used for hypothesis testing as in the large trials in
section 3.2, based on the assumption that (especially in a trial where patients
are recruited sequentially) the experimenter might not know at the start of
the trial the total number of patients she will be able to recruit, so more
appropriate critical values cannot be estimated a priori. Based on the same
reasoning we continue to use the original choice of d = 0.995.
Table 3 shows the full results of the simulations. Due to the greatly
reduced sample sizes, all designs now achieve much lower power, a common
situation in drug development for rare diseases. In a situation where N  T ,
statistical power is important, and CUC and CG offer the best compromise.
Both perform similarly well, achieving higher power than FR, and offering a
marked improvement in patient welfare compared with FR. However, if the
trial subjects comprise most of the total population to be treated (T/N ≈ 1),
then GI and RBI provide the best patient outcome throughout the trial.
The results in the table for the batched approaches show that, as ex-
pected, as the delay in recruitment is more severe the advantages of TSB
and TPB over FR are significantly reduced (though both designs still offer
important patient welfare advantages). Noticeably, the effect on power and
patient welfare of a severe delay in the controlled version (i.e. TPB) differs to
that of the uncontrolled variant (TSB). The controlled version has its power
levels reduced as the delay increases (while the opposite happens to TSB).
TP improves power over FR by matching the allocation of the control arm to
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H0 : µ0 = µ1 = µ2 = µ4 = 0 H1 : µ0 = 0, µ1 = µ2 = 0.178, µ3 = 0.545
Cα α Ep∗ (s.d.) EO (s.d.) (1− β) Ep∗ (s.d.) EO (s.d.)
FR 2.062 0.0490 0.2497 (0.05) 0.0009 (0.13) 0.2975 0.2490 (0.05) 0.2260 (0.13)
TS 2.198 0.0510 0.2491 (0.09) -0.0001 (0.13) 0.2592 0.3594 (0.11) 0.2779 (0.13)
TSB 2.103 0.0499 0.2489 (0.08) -0.0010 (0.13) 0.2901 0.3245 (0.09) 0.2625 (0.13)
RBI 2.041 0.0471 0.2497 (0.22) 0.0000 (0.13) 0.1619 0.5351 (0.26) 0.3529 (0.16)
RGI 2.070 0.0565 0.2489 (0.14) 0.0013 (0.12) 0.2344 0.4725 (0.18) 0.3258 (0.15)
UCB 2.223 0.0444 0.2475 (0.14) -0.0028 (0.13) 0.1730 0.4772 (0.18) 0.3296 (0.15)
KLU 2.154 0.0503 0.2492 (0.10) -0.0023 (0.13) 0.2452 0.4194 (0.13) 0.3043 (0.13)
CB 1.691 0.0515 0.2522 (0.37) -0.0006 (0.12) 0.0775 0.4569 (0.46) 0.3239 (0.22)
GI 1.955 0.0477 0.2529 (0.24) 0.0015 (0.13) 0.1226 0.5445 (0.29) 0.3585 (0.17)
CG 1.923 0.0523 0.4100 (0.17) -0.0002 (0.12) 0.3806 0.4061 (0.22) 0.2742 (0.15)
CUC 1.934 0.0573 0.3445 (0.10) -0.0011 (0.13) 0.3851 0.3821 (0.15) 0.2670 (0.14)
TP 2.027 0.0462 0.2275 (0.04) 0.0011 (0.12) 0.3174 0.3256 (0.10) 0.2534 (0.13)
TPB 2.027 0.0472 0.1751 (0.04) -0.0019 (0.12) 0.2674 0.3141 (0.07) 0.2620 (0.13)
UB 0.0000 (0.13) 1.0000 (0.00) 0.5450 (0.13)
Table 3: Comparison in 104 trial replicates of operating characteristics of different four-
arm trial designs of size T = 64, under both hypotheses. α: type I error rate; Ep∗: mean
proportion of patients in a trial assigned the best treatment; (s.d.): standard deviation for
each measurement; EO: mean patient outcome; (1−β): statistical power. UB: theoretical
upper bound from assigning all patients best treatment.
that of the best performing arm, therefore increasing the allocation to these
two arms over the other arms. With a larger delay TBP will allocate larger
number of patients to all arms which therefore reduces its marginal power
levels compared to TP. For TSB the power improvement is explained because
the design cannot skew allocation to the best arm as fast as with TS, thus
allocating more patients to all arms when compared to TS.
One distinctive feature of the results is that the Type I error rate α in
the UCB trial is lower than the expected 5%, at just 4.4%. As explained
above, the same critical values for hypothesis testing have been used as in
§3.2, since the experimenter might not known in advance the total number
of patients to be recruited. Figure 3.5 shows how the appropriate critical
value C0.05 for hypothesis testing with a Type I error rate α = 5% varies
according to the size T of the trial. For most trial designs, there is little
variation in C0.05 as T increases. However, for the UCB trial, C0.05 increases
significantly with T ; as a result, the appropriate critical value to ensure a
5% Type I error rate is lower for the smaller 64 person trial, at C0.05 = 2.10,
compared to C0.05 = 2.22 for the 302 person trial. Therefore, the 64 person
trial conducted at the higher critical value of 2.22 generates a low Type I error
rate, and the power is even lower than it could be if the test was relaxed by
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lowering the critical value to 2.10. As a result, the UCB mechanism may be
unsuitable for trials where the total number of patients to be recruited is not
known in advance. This effect is less pronounced in the KLU variant making
it more suitable in that case.
Since the trial size was much smaller than expected, there is a motivation
to consider if using a smaller value for d would affect results, as a smaller
discounting factor corresponds to putting less value on learning for the future.
Note that, when varying the discount factor, we might expect the distribution
of the test statistic Z to change, and so critical values for the hypothesis tests
would have to be recalculated for each discount factor for the Gittins index
designs, via a Monte Carlo simulation as in §3.2. In simulations not included
here we found that for this trial setting in all of GI, RGI and CG there
is no significant variation in patient outcome between discount factors in
{0.9, 0.95, 0.995, 0.99}.
4 Conclusions and discussion
The simulation results provided by this paper illustrate how the index-based
response-adaptive design derived from the MABP can lead to significant
improvements in patient welfare also with a normally distributed endpoint.
In all situations, designs based on the Gittins index achieved the largest
patient welfare gain over FR trials or myopic designs currently in use in
drug development such as TP. However, there are a number of limitations
to the effectiveness of the purely deterministic Gittins index design that still
prevail. As in the binary case, the Gittins index rule exhibits considerably
lower power than FR, and whilst the loss of power can be alleviated to some
extent by the introduction of random perturbations to the indices (RGI), in
the two-arm trial the power achieved is still not sufficient for most clinical
trials unless the exploration term is correctly calibrated.
In a multi-armed case, the patient welfare advantages of adaptive de-
signs, and GI-based particularly, over FR are the largest. Moreover, there
are adaptive designs that can offer more power than FR together with a
patient benefit advantage, making them suitable for drug development for
common conditions. In the four-arm case based on a real trial we studied,
a small deviation from optimality by protecting the allocation of the control
treatment (CG and CUC) offers a power close to (or even above) FR’s while
still providing considerable patient benefit. In contexts where power is rela-
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tively less important (if there are very few disease sufferers outside the trial),
GI, RGI or UCB offer even better patient welfare at the expense of a power
reduction.
There are designs that increase power levels of the UCB algorithm by
introducing modifications to improve its asymptotic regret bounds, as shown
for KLU in [6]. However, such power gains require a very large number
of patients in the trial to be also accompanied by similar patient welfare
advantages. For example, KLU dominates over UCB under both criteria only
in scenarios where trials had more than thousands of patients. For smaller
(and more realistic) trial sizes, as the ones considered in this paper, UCB
had better patient welfare and less power than KLU. Nevertheless, rules like
KLU offer a good trade-off between the two objectives and can be suitable
designs for common diseases.
An important observation drawn from the simulations provided by this
paper is that the type I error deflation of the GI observed for the Bernoulli
case does not hold in the normally distributed case. Actually, if no correction
is introduced using a standard test will result in an important type I error
inflation. In this work we have outlined a simulation based procedure that
can be used to prevent this inflation.
As pointed out in [5], trying to shoehorn trials employing an adaptive de-
sign from a Bayesian viewpoint into traditional frequentist hypothesis tests
may not be the most appropriate method of inference. Alongside the statisti-
cal community’s faith in randomisation is a trust in frequentist inference, so
this is generally used even in Bayesian trials to make the results as persuasive
as possible. But, the inferential power and the potential patient benefit from
adaptive trials could be improved by applying Bayesian inference methods
combined with the use of prior data. Further research could seek an appro-
priate method of Bayesian inference based on index-based adaptive trials,
e.g. by considering which arm the adaptive design is favouring most at the
end of the trial, or by incorporating information derived from historical data.
None of the Bayesian allocation mechanisms considered here manages
to completely eliminate the statistical bias phenomenon; further research is
needed to seek an alternative mechanism or a means of accounting for the bias
introduced. Moreover, they all carry a level of selection bias which, while not
studied in the simulations included in this paper, could lead to much greater
bias in clinical trials on a real population. Further research is needed to in-
vestigate whether significant practical problems will arise from selection bias
in real trials, and whether random perturbations to the indices are sufficient
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to eliminate these problems. Alternatively, to overcome this limitation fur-
ther research could repeat the idea introduced in [24] to randomise group of
patients based on probabilities determined by the Gittins Indices for trials
with continuous endpoints. For the procedures that protect allocation to the
control arm we recommend a randomised implementation (where a patient
is randomised to control or experimental arms with probabilities 1/(K + 1),
1−1/(K+1) respectively and then allocated to experimental arms according
to the index rule). A systematic allocation to control arm (i.e., 1 in every
K + 1 patient is allocated to control) while in theory is equivalent to its ran-
domised counterpart in practice is subject to a very high degree of selection
bias.
Some adaptive trials are designed to take account of covariates in the trial
population (e.g. age, weight, blood pressure) which might affect the treat-
ment response, by ensuring the allocations are balanced across the covariate
factors [3] . Other trials incorporating covariate information combined with
response-adaptive procedures with the aim of identifying superior treatments
more quickly, mainly treatments that work better within subgroups, is an es-
sential requirement to make personalised medicine possible. Some work has
been done on incorporating covariates into the one-armed bandit problem,
yet further research is needed to extend the approach to multi-armed bandits
used in this work to clinical trials with biomarkers. See [27], [19] and [16].
None of the adaptive designs considered formally accounts for the esti-
mated population size. The index-based approaches indirectly can consider
that by appropriate selection of the discount factor. However, the results in
this paper suggest that the choice between implementing a traditional FR
design or an adaptive design should depend on the current belief of how large
the population of patients outside the trial is.
Finally, the results presented in this paper have highlighted that further
analogous research is needed to extend these results and address potential
specific issues to trials with other endpoints, such as continuous endpoints
that are not normally distributed.
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Figure 2.1: Gittins Index values (normal reward process, known variance) for various
discount factors d
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Figure 3.1: The posterior mean x¯k,t of each treatment arm’s outcomes after each patient
in a typical GI trial under H0
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Figure 3.2: Histograms of empirical distributions of the test statistic Z in GI trials, imple-
mented under each hypothesis. Also marked is the standard normal distribution which Z
should follow in the FR trial (red). The sample mean Z¯, standard deviation SZ and an em-
pirical 95th-percentile C0.05 have been calculated under H0. The empirical 95th-percentile
under H0 will correspond to the critical value for hypothesis testing, and is marked by a
vertical dotted line on the histograms.
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(c) H1, control arm k = 0
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(d) H1, experimental arm k = 1
Figure 3.3: E(x(t)k −µk), the mean (across the trial realisations) of the bias in the estimated
outcome of each treatment after a total of t patients have been treated across both arms
in the trial, under each scenario (two-arm trial simulations).
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(b) H0, experimental arm k = 3
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(d) H1, experimental arm k = 3
Figure 3.4: E(x(t)k − µk), the mean (across the trial repeats) of the bias in the estimated
treatment outcome of each drug under each scenario in the four arm trial (large sample
size)
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Figure 3.5: Empirical critical values C0.05 for one-tailed testing to maintain 5% FWER in
the four arm trial design, against number T of patients in the trial
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Appendix I: Controlling the family-wise type I
error rate
In order to control the FWER when carrying out multiple testing, we need
to consider the joint distribution of Z1, . . . , Zk. We have, for 1 ≤ j 6= k ≤ K,
cov (Zj, Zk) = cov
 Xj−X0
σ
√
1
nj
+
1
n0
, Xk−X0
σ
√
1
nk
+
1
n0

= 1
σ2
1√
1
nj
+
1
n0
1√
1
nk
+
1
n0
Var
(
X0
)
by the independence of Zj and Zk. Using the fact that Var
(
X0
)
= σ
2
n0
,
cov (Zj, Zk) =
[(
1 + n0
nj
)(
1 + n0
nk
)]−1
2
.
Error rates are lowest when the variance of the sample means is minimised,
which corresponds to the trial being well balanced: in a RCT trial with fixed
equal randomisation all the sample sizes are (asymptotically) equal, so we
will have a good approximation for n0 ≈ n1 ≈ · · · ≈ nK and cov (Zj, Zk) ≈ 12 .
Hence, under H0,G, δ1 = · · · = δK = 0 and
Z = (Z1, . . . , ZK) ∼ NK (0,ΣK)
where ΣK is the K ×K matrix given by
(ΣK)ij =
{
1, i = j
1
2
, i 6= j .
So we would expect a RCT trial to control the FWER at level α by using
critical value Cα satisfying
Cαˆ
−∞
· · ·
Cαˆ
−∞
φΣK (x1, . . . , xK)dx1 . . . dxK = 1− α (4.1)
where φΣK is the probability density function of a multi-variate normal
NK(0,ΣK) distribution, i.e. ensuring that
P
[
max
k=1,...,K
Zk ≤ Cα
]
= 1− α. (4.2)
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Appendix II: Calculating empirical cut-off values
to control the type I error rate
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(c) RBI trial under H0
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Figure 4.1: Histograms of empirical distributions of the test statistic Z0,1 in TS, RBI, RGI,
UCB, KLU and CB two-arm trials, implemented under each hypothesis (as in Figure 3.2).
Also marked is the standard normal distribution which Z0,1 should follow in the FR trial
(red). For each design, the sample mean Z¯0,1, standard deviation SZ0,1 and an empirical
95th-percentile C0.05 have been calculated under H0. The empirical 95th-percentile under
H0 will correspond to the critical value for hypothesis testing, and is marked by a vertical
dotted line on the histograms.
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